医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

SpinalCyte, LLC Receives New Australian Patent for Spinal Disc Tissue Engineering

2015年10月14日 PM11:17
このエントリーをはてなブックマークに追加


 

HOUSTON

SpinalCyte, LLC, a Texas-based tissue engineering technology company focused on regrowth of the spinal disc nucleus using human dermal fibroblasts, announced today the issuance of Australian Patent No. 2013257540, “Methods and Compositions For Repair Of Cartilage Using An In Vivo Bioreactor.” The technology described in the patent involves using an absorbable membrane scaffold to support the growth of new cells populating the nucleus. Other claims provide for a semi-permeable membrane which allows for diffusion of nutrients. The membrane will be used to transfer the intermittent hydrostatic pressure onto the differentiating chondrocyte cells.

“The new Australian Patent broadens our protection internationally and protects our unique technology in one of the fastest growing markets for biologic repair of tissue,” said Pete O’Heeron, Chief Executive Officer. “We are pleased the Australian Commissioner of Patents has recognized the uniqueness of our technology.” SpinalCyte’s patent portfolio includes 11 U.S. and foreign patents issued and directly owned by the company, along with 17 patents pending.

About SpinalCyte, LLC

Based in Houston, Texas, SpinalCyte, LLC is a tissue engineering technology company founded for the purpose of developing an innovative and autologous solution for spinal nucleus replacement using human dermal fibroblasts. The goal of SpinalCyte is to develop a cartilage regeneration technology using autologous dermal cells harvested from the patient. To date, SpinalCyte has been funded entirely by angel investors.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151014005351/en/

CONTACT

SpinalCyte, LLC
Pete O’Heeron, 281.461.6211
CEO
pete@spinalcyte.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent